Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06452160
Status:
RECRUITING
Last Update Posted:
2024-06-13
First Post:
2024-06-05
Brief Title:
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
Sponsor:
BridGene Biosciences Inc
Organization:
BridGene Biosciences Inc
Study Overview
Official Title:
A Phase I Clinical Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Patients With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this open-label dose escalation and dose expansion Phase I clinical trial is to evaluate the safety tolerability pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None